Companies · Biotechnology
EMERYVILLE · Biotechnology
Diligence memoA one-page analyst read on Origen Therapeutics Inc /Ca — recommendation, valuation, rhythm, risks.→Origen Therapeutics Inc /Ca looks over-valued against its niche peers and is dormant on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
Origen Therapeutics Inc /Ca is one of 4293 Biotechnology companies tracked from EMERYVILLE. By capital raised it ranks in the long tail (ahead of 38% of sector peers), and mid-pack by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.
Round size and date are reported; the stage label is inferred from round size (latest is Seed — a $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.
Not enough modeled valuation points to chart a trajectory.
Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 38% of sector peers (real $). Modeled value above 68% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #9 of 151.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Denali Medical II, Inc. | Seed | $4.0M | $177.6M | 2.05× |
| Signum Biosciences, Inc. | Seed | $4.0M | $177.6M | 2.05× |
| Health Elements, LLC | Seed | $4.0M | $177.6M | 2.05× |
| Nkt Therapeutics Inc | Seed | $4.0M | $177.6M | 2.05× |
| Surface Logix Inc | Seed | $4.0M | $177.6M | 2.05× |
| Fe3 Medical, Inc. | Seed | $5.4M | $177.1M | 2.05× |
| Proteonomix, Inc. | Seed | $3.8M | $169.0M | 1.95× |
| SRS Medical Systems, Inc. | Seed | $3.8M | $167.4M | 1.93× |
| Origen Therapeutics Inc /Ca this company | Seed | $3.7M | $166.2M | 1.92× |
| Vivebio, LLC | Seed | $3.7M | $163.1M | 1.88× |
| O2 Medtech Inc | Seed | $7.1M | $160.3M | 1.85× |
| Biothera, Inc. | Seed | $3.5M | $155.4M | 1.79× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Seed | $3.7M | 2010-07-28 | $18.7M | $166.2M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| David W. Carter | — | 1 other | 2010-07 |
| Lynda W. Wijcik | — | — | 2010-07 |
| Robert W. Kay | — | — | 2010-07 |
| Spencer W. Wang | — | — | 2010-07 |
| Timothy W. Harris | — | — | 2010-07 |
Origen Therapeutics Inc /Ca is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Nexstim Plc | Biotechnology | Seed | $3.7M | $166.4M | same sector · same stage |
| Gladius Pharmaceuticals Corp | Biotechnology | Seed | $3.8M | $134.2M | same sector · same stage |
| Targegen Inc | Biotechnology | Seed | $3.7M | $165.6M | same sector · same stage |
| QT Holdings Corp. | Biotechnology | Seed | $3.8M | $145.9M | same sector · same stage |
| SRS Medical Systems, Inc. | Biotechnology | Seed | $3.8M | $167.4M | same sector · same stage |
| Initial Therapeutics, Inc. | Biotechnology | Seed | $3.8M | $168.6M | same sector · same stage |
| Tilos Therapeutics, Inc. | Biotechnology | Seed | $3.8M | $135.4M | same sector · same stage |
| Promethean Surgical Devices, Inc. | Biotechnology | Seed | $3.7M | $163.6M | same sector · same stage |
See where Origen Therapeutics Inc /Ca sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Origen Therapeutics Inc /Ca, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.